Learn More
Invitrogen™ hu14.18-IL2 Biosimilar Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody
£397.00 - £1002.00
Specifications
| Antigen | hu14.18-IL2 Humanized Biosimilar |
|---|---|
| Concentration | 1 mg/mL |
| Content And Storage | -20°C, Avoid Freeze/Thaw Cycles |
| Applications | ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance |
| Classification | Recombinant Monoclonal |
| Product Code | Brand | Quantity | Price | Quantity & Availability | |||||
|---|---|---|---|---|---|---|---|---|---|
| Product Code | Brand | Quantity | Price | Quantity & Availability | |||||
30283652
![]() |
Invitrogen™
MA559449 |
100 μg |
£397.00
100µg |
Please sign in to purchase this item. Need a web account? Register with us today! | |||||
|
30284532
|
Invitrogen™
MA559450 |
1 mg |
£1002.00
1mg |
Please sign in to purchase this item. Need a web account? Register with us today! | |||||
Description
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °. This antibody can also be cross referenced by the term EMD 273063.
Hu14.18-IL2 is a humanized monoclonal antibody covalently linked to two interleukin-2 (IL-2) molecules. The hu14.18 component specifically targets GD2, a disialoganglioside abundantly expressed on tumor cells, especially in neuroblastoma and melanoma. Meanwhile, IL-2 stimulates the proliferation and activation of immune cells such as natural killer (NK) cells and T cells. GD2, also known as GD2 ganglioside, is a tumor-associated glycolipid antigen that is overexpressed in a variety of cancers, particularly those derived from neuroectodermal tissues. Structurally, GD2 contains three carbohydrate residues and two sialic acids bonded to a ceramide tail, which is embedded in the outer plasma membrane. This compound plays a critical role in cell surface glycosylation changes during malignant transformation and is ranked high as a target for cancer vaccine development.Specifications
| hu14.18-IL2 Humanized Biosimilar | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Recombinant Monoclonal | |
| Lyophilized | |
| IgG1 | |
| Human | |
| Primary | |
| Protein A |
| 1 mg/mL | |
| ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance | |
| Unconjugated | |
| Human | |
| RUO | |
| 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 | |
| Antibody |
Your input is important to us. Please complete this form to provide feedback related to the content on this product.